The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Trombetta, Bianca A., Becky C. Carlyle, Aaron M. Koenig, Leslie M. Shaw, John Q. Trojanowski, David A. Wolk, Joseph J. Locascio, and Steven E. Arnold. 2018. “The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease.” PLoS ONE 13 (3): e0193707. doi:10.1371/journal.pone.0193707. http://dx.doi.org/10.1371/journal.pone.0193707. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1371/journal.pone.0193707                                                                                                                                                                                                                            |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35982045                                                                                                                                                                                                             |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysioologies in Alzheimer’s disease

Bianca A. Trombetta¹, Becky C. Carlyle¹, Aaron M. Koenig¹, Leslie M. Shaw², John Q. Trojanowski², David A. Wolk³, Joseph J. Locascio¹, Steven E. Arnold¹*

¹ MGH Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States of America; ² Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, United States of America; ³ Penn Memory Center, Department of Neurology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, United States of America

* searnold@mgh.harvard.edu

Abstract

Objective

Alzheimer’s disease (AD) is a complex neurodegenerative disease driven by multiple interacting pathophysiological processes that ultimately results in synaptic loss, neuronal death, and dementia. We implemented a fit-for-purpose modeled approach to qualify a broad selection of commercially available immunoassays and evaluate the biotemporal stability of analytes across five pathophysiological domains of interest in AD, including core amyloid-β (Aβ) and tau AD biomarkers, neurodegeneration, inflammation/immune modulation, neurovascular injury, and metabolism/oxidative stress.

Methods

Paired baseline and eight-week CSFs from twenty participants in a clinical drug trial for mild cognitive impairment (MCI) or mild dementia due to AD were used to evaluate sensitivity, intra-assay precision, inter-assay replicability, and eight-week biotemporal stability for sixty unique analytes measured with commercially available single- and multi-plex ELISA assays. Coefficients of variation (CV) were calculated, and intraclass correlation and Wilcoxon signed rank tests were applied.

Results

We identified 32 biomarker candidates with good to excellent performance characteristics according to assay technical performance and CSF analyte biotemporal stability cut-off criteria. These included: 1) the core AD biomarkers Aβ₁−₄₂, Aβ₁−₄₀, Aβ₁−₃₈, and total tau; 2) non-Aβ, non-tau neurodegeneration markers NfL and FABP3; 3) inflammation/immune modulation markers IL-6, IL-7, IL-8, IL-12/23p40, IL-15, IL-16, MCP-1, MDC, MIP-1β, and
YKL-40; 4) neurovascular markers Flt-1, ICAM-1, MMP-1, MMP-2, MMP-3, MMP-10, PIGF, VCAM-1, VEGF, VEGF-C, and VEGF-D; and 5) metabolism/oxidative stress markers 24-OHC, adiponectin, leptin, soluble insulin receptor, and 8-OHdG.

Conclusions

Assays for these CSF analytes demonstrate consistent sensitivity, reliability, and biotemporally stability for use in a multiple pathophysiological CSF biomarker panel to profile AD. Their qualification enables further investigation for use in AD diagnosis, staging and progression, disease mechanism profiling, and clinical trials.

Introduction

Alzheimer’s disease (AD) and related disorders (including Lewy body dementias, frontotemporal lobar degenerations, and vascular cognitive impairment and dementias) are complex neurodegenerative diseases driven by vicious pathophysiological cycles of protein misfolding [1], inflammation [2,3], neurovascular dysfunction [4], oxidative injury [5,6], and disruption of metabolic pathways [7,8]. To varying degrees, these promote excitotoxicity [9], autophagy [10], apoptosis [11], and necrosis [12], with resultant synaptic loss and neuronal death [13,14]. Progressive dementia of insidious onset is the clinical manifestation of these processes that evolve over years to decades prior to expression of clinical symptoms [15]. While the core amyloid-β (Aβ) and tau biomarkers of AD [16,17] are highly associated with the presence of signature plaque and tangle pathological hallmarks of AD in the brain [16], they do not assess other fundamental biochemical aspects of the disease, such as non-amyloid and non-tau neurodegeneration or metabolic, immune, and neurovascular dysfunction [18–21]. A panel of robust biomarkers that directly reflect these concomitant pathophysiologies may prove a better indicator of disease diagnosis [22,23], subtypes, staging, and activity, as well as treatment-specific target engagement.

As clinical trials continue to move towards pre-symptomatic individuals and disease prevention, it is critical to establish biofluid markers that may sensitively detect biochemical changes associated with disease onset and the intersecting pathophysiologies that drive disease progression [24,25]. A panel of analytes that represent multiple facets of AD pathology and pathophysiology, as opposed to a single marker, may offer increased specificity and sensitivity in diagnosis [22,23], but more importantly, may also profile AD subtypes to enable precision medicine. Current clinical trials for AD focus on disease modification with investigational new agents that target general neuroprotection, neuroinflammation, metabolic and oxidative dysfunction, and neurovascular dysfunction. Determining how active each of these pathophysiologies are in a given patient with pathway-oriented biomarkers may help guide choice of therapy, and would also be important for demonstrating and monitoring the effects of pharmacodynamic target engagement.

A key consideration for the development of any biomarker is the reproducibility of results within and across times and laboratories. While the core AD biomarkers have been extensively evaluated in terms of precision, pre-analytical factors affecting measures, and utility in clinical research and care [21,26–29], validations for newer candidate cerebrospinal fluid (CSF) biomarkers are still in an early phase. Of particular importance for clinical trials is confidence in the stability of biomarkers over short-term repeat collections from the same individual, independent of disease-related pathophysiological changes [30,31]. Highly dynamic analytes whose
levels fluctuate widely from day to day as a result of diet, restless sleep, or other biorhythms or environmental influences, would not prove reliable in a clinical trial where a limited number of samples are collected over long periods of time. Like technical precision of an assay, this “biotemporal stability” of a biomarker needs to be considered in sample size determinations and study design so the measurements reflect true disease progression or drug effect as opposed to random noise. Low baseline variability over brief periods of time, as has been established with the core AD biomarkers [32–36], increases the value of a CSF biomarker as a routine measurement in a clinical setting, suggesting that it may be sensitive enough to detect disease-related differences, disease progression over longer periods of time, or biochemical changes in response to intervention [31]. While there are a few reports describing short-term intra-individual variation of AD-relevant biomarkers in serum [31,37] and over longer intervals (annual) in CSF [35], stability over shorter intervals in CSF is rarely investigated or reported. Opportunities to conduct such analyses are scarce, as multiple lumbar punctures within short timeframes are seldom performed, even in the context of clinical research.

We implemented a fit-for-purpose modeled approach for evaluating and qualifying a broad selection of commercially available immunoassays for exploratory use with CSF. The assays represent five key domains of AD pathophysiology: 1) core AD amyloid-β and total tau biomarkers, 2) non-αβ and non-tau neurodegeneration, 3) inflammation and immune modulation, 4) neurovascular markers, and 5) metabolism and oxidative stress. We identified 32 biomarker candidates with excellent performance characteristics by assessing technical assay reliability and biotemporal intra-individual variation of each biomarker in CSFs collected at two timepoints over an eight-week interval from individuals with mild cognitive impairment (MCI) or mild dementia due to AD. These candidate analytes may be used to develop a broad, practical biomarker panel that simultaneously portrays the diverse pathophysiological processes involved in AD and related disorders. These rigorously validated analytes should perform consistently and reliably in profiling the complex pathophysiology of AD and monitoring changes during disease progression and intervention, ultimately enabling clinical trials and allowing personalized treatment.

**Materials and methods**

**Study participants**

CSFs were obtained at baseline and after 8 weeks as part of a pilot randomized placebo-controlled clinical trial investigating the effects of the drug metformin (versus placebo) in MCI/AD (NCT01965756) [38]. All subjects provided written informed consent for participation and use of CSF in future research in Human Subjects Institutional Review Board (IRB)-approved protocols at the University of Pennsylvania. All subjects had a clinical diagnosis of amnestic MCI or mild dementia due to AD. Demographic and clinical characteristics are presented in Table 1. As previously described [38], eligibility criteria included: age 55 to 80 years at screening, clinical diagnosis of MCI or mild dementia due to AD with a Clinical Dementia Rating [39] global ≤ 1.0, Mini-Mental State Examination [40] > 19, Geriatric Depression Scale [41] total < 6 to exclude concomitant depression, Modified Hachinski Ischemic Scale [42] score < 4 to exclude subjects with potential vascular etiology to their cognitive complaints, fasting blood glucose < 110 or HgbA1c < 6.0 to exclude subjects with diabetes or prediabetes, and at least one positive biomarker consistent with AD (i.e. previous Aβ CSF, fluorodeoxyglucose or Aβ positron emission tomography, or volumetric MRI). Individuals on an acetylcholinesterase inhibitor were required to be on a stable dose for at least 2 months prior to screening. Based on prerequisites for the intervention under investigation, potential subjects were ineligible if they had past or current diabetes or renal disease, evidence of
infarcts, focal intracranial lesions or other neurodegenerative conditions, or unstable medical or psychiatric illness. A total of 20 participants were enrolled: 9 women and 11 men, with a mean age of 70.1 years.

APOE 4 carrier status was inferred following the conclusion of the study using a validated immunoassay (K4699, BioVision) to measure Apolipoprotein E (ApoE) 4 in plasma according to manufacturer’s instructions.

Cerebrospinal fluid collection and measurement overview

CSF samples were collected by lumbar puncture (LP) at baseline and again at 8 weeks with adherence to ADNI protocol (http://www.adni-info.org/). The procedure was performed between 8 a.m. and 10 a.m. in all participants to minimize effects of diurnal variation. Using 24-gauge Sprotteatraumatic needles, 20 mL of CSF was collected into polypropylene syringes according to standard procedure. Within 30 minutes of collection, CSF was aliquoted into 0.5 mL polypropylene tubes, bar-coded, frozen, and stored at -80˚C for subsequent analysis. CSFs were tested in duplicate in each of three experimental blocks to assess the intra- and inter-plate reliability of candidate assays. Repeat CSFs from 9 subjects in the 8-week placebo arm were used in paired assays and tested in each block to determine short-term intra-individual variation. After initial data inspection, samples from one participant in the metformin group were disregarded due to hemolytic contamination, resulting in artificially elevated analyte concentrations. Assays were conducted in the Arnold Lab at the Massachusetts General Hospital Institute for Neurodegenerative Diseases (MIND). In addition, amyloid-β peptide 1-42 (Aβ1-42), total tau (tTau), and phospho-tau (pTau) data were available from prior testing in these samples at the ADNI Biomarker Core / Shaw Lab at the University of Pennsylvania [38].

Biochemical procedures

The performance characteristics of 60 unique potential biomarker analytes were evaluated in twenty single or multi-plexed panel kits (Table 2). CSF concentrations of 54 analytes were examined using the Meso-Scale Discovery (MSD) platform with commercially available simplex and multi-plex electrochemiluminescent (ECL) immunoassays (Meso-Scale Diagnostics, LLC, Rockville, MD). Along with replicating the core AD biomarkers Aβ1-42 and tTau, we tested other potential analytes in the pathophysiological domains of neurodegeneration,
metabolism and oxidative damage, neurovascular injury, and inflammation/immune modulation. Fourteen MSD assay panels for biomarkers of interest were chosen based on a number of factors including a priori pathophysiological relevance, assay availability, previous assay use in the literature, specific reported features of concentration sensitivity and range, previous use in CSF (if any) and previous findings in AD. An additional 6 colorimetric ELISA kits were used to measure markers not available through MSD. All kits were purchased in bulk to minimize lot-to-lot variability. Assays were performed according to manufacturer’s specifications and samples diluted per assay requirements. For kits commercially validated for use with CSF, samples were diluted according to published dilution recommendations. These included: V-PLEX Plus Human Total Tau, V-PLEX Plus Aβ Peptide Panel 1 (6E10), U-PLEX Plus Human α-Synuclein, V-PLEX Plus Vascular Injury Panel 2, and NF-light (NfL) ELISA. Recommended dilutions ranged from 1:2–1:8. The remaining 15 kits did not include published dilution recommendations for CSF samples, necessitating experimental determination of the minimum required dilution.

Table 2. Evaluated immunoassay kits, including assay characteristics and CSF dilutions.

| Commercial panel name                                      | Company       | Catalog number | Biomarker targets | CSF Dilution |
|-------------------------------------------------------------|---------------|----------------|-------------------|--------------|
| **Core AD assays**                                          |               |                |                   |              |
| V-PLEX Plus Human Total Tau                                | MSD           | K151LAG        | total tau         | 1:4          |
| V-PLEX Plus Aβ Peptide Panel 1 (6E10)                      | MSD           | K15200G        | Aβ1-40, Aβ1-42   | 1:2          |
| **Aβ and tau-independent neurodegeneration assays**        |               |                |                   |              |
| U-PLEX Plus Human α-Synuclein                              | MSD           | K151WKP        | α-Synuclein       | 1:8          |
| Human FABP3                                                 | MSD           | K151HTD        | FABP3            | Neat¹        |
| NfL (Neurofilament-light) ELISA                            | UmanDiagnostics | 10–7002     | Neurofilament-light | 1:2          |
| **Metabolic assays**                                        |               |                |                   |              |
| 24(S)-Hydroxycholesterol ELISA                             | Enzo Life Sciences | ADI-900-210-0001 | 24-OHC          | 1:2          |
| Human Active GLP-1 (7–36) amide, Insulin, Glucagon, Leptin | MSD           | K15173C        | Active GLP-1 (7–36) amide, Insulin, Glucagon, Leptin | Neat¹        |
| Human Adiponecin                                            | MSD           | K151BXC        | Adiponecin       | 1:10         |
| Insulin Receptor Human ELISA                               | BioVendor     | RD1991041200R  | Soluble Insulin Receptor | 1:2²        |
| VGF Nerve Growth Factor Inducible (VGF)                    | Höppl Diagnostika | SEB166Hu   | VGF              | Neat¹        |
| **Oxidative stress assays**                                |               |                |                   |              |
| OxiSelect CML Competitive ELISA                             | Cell Biolabs, Inc. | STA-816 | CML               | Neat¹        |
| OxiSelect Oxidative DNA Damage ELISA                        | Cell Biolabs, Inc. | STA-320 | 8-OHdG            | Neat¹        |
| **Neuroinflammatory and vascular injury assays**           |               |                |                   |              |
| V-PLEX Plus Angiogenesis panel 1 (human)                   | MSD           | K15190G        | FGF (basic), Flt-1, PIGF, Tie-2, VEGF-C, VEGF-D | Neat¹        |
| V-PLEX Plus Chemokine Panel 1 (human)                      | MSD           | K15047G        | Eotaxin, Eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC | Neat¹        |
| V-PLEX Plus Cytokine panel 1 (human)                       | MSD           | K15050G        | IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF | Neat¹        |
| Human MMP 2-Plex Ultra-Sensitive Panel                     | MSD           | K15033C        | MMP-2, MMP-10    | Neat¹        |
| Human MMP 3-Plex Ultra-Sensitive Panel                     | MSD           | K15034C        | MMP-1, MMP-3, MMP-9 | Neat¹        |
| V-PLEX Plus Proinflammatory Panel 1 (human)                | MSD           | K15049G        | IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, TNF-α | Neat¹        |
| V-PLEX Plus Vascular Injury Panel 2 (human)                | MSD           | K15198G        | CRP, ICAM-1, SAA, VCAM-1 | 1:5         |
| Human YKL-40                                               | MSD           | K151NHD        | YKL-40           | 1:50²        |

¹ Datasheet only included published dilution factors for serum and plasma. Dilution factor required for CSF was determined experimentally. Abbreviations: MSD, Meso Scale Diagnostics, LLC.

https://doi.org/10.1371/journal.pone.0193707.t002
(MRD) prior to final analysis (designated with a † in Table 2). For many of these assays, CSF samples were measured neat to allow concentrations to fall within a detectable range.

The plate design scheme for sample wells and reliability measures is shown in Fig 1. Each plate contained the entire cohort of CSF samples, and all paired CSF samples per subject were included on the same assay in adjacent wells. This design ensured that plate-to-plate variability would not compromise biotemporal analysis of analyte concentrations between paired repeat-collection CSFs. Each CSF sample was assayed in duplicate per plate, and each plate experiment was replicated three times. A different 0.5 mL aliquot of sample was used for each assay replicate. Serially diluted standard curves and spiked controls were included on every plate and measured in duplicate.

Numerical data obtained on the MSD platform were generated using the MSD Discovery Workbench 4.0 software. For colorimetric ELISA kits, absorbance values were collected using a microplate reader (Victor 2 Multi-Label Microplate Reader, Perkin Elmer-Wallac) and sample concentrations manually calculated against the standard curve using a 4-Parameter Logistic Regression.

**Statistical analysis**

Statistical analyses were conducted using SPSS Statistics 24.0 (IBM Corp., Armonk, N.Y., USA), R 3.3.2 [43], and RStudio 1.0.136 [44]. CSF analyte concentrations were natural-logarithm transformed prior to computing relevant statistical tests that required normally distributed residuals.

A number of assays examined here had not been reported previously in CSF. Consistent detection of an analyte in plasma does not ensure detection in CSF, as the protein may not be generated in the CNS, its levels may be altered by blood brain barrier (BBB) selectivity, and/or
its detection may be compromised by matrix effects. To verify whether each assay had sufficient sensitivity to detect an analyte(s) in CSF, we compared sample concentrations of analytes to the assay’s lower limit of detection (LLOD), specific to each individual plate and analyte. The LLOD was calculated by the Discovery Workbench 4.0 software as 2.5 standard deviations above the background signal. For colorimetric assays, the published LLOD was used as the assay’s sensitivity threshold. A biomarker assay was considered to be satisfactorily sensitive if it was consistently measured above the assay LLOD in > 80% of samples across all plates.

For use in any comparative study, it is critical that repeat measures are technically reliable. Moreover, to detect change with treatment in the context of typically slow disease progression, CSF levels should be biologically consistent and not fluctuate widely over short periods of time. An experimental scheme was designed to assess all forms of assay stability for analytes that passed LLOD criteria: intra-assay, inter-assay, and biotemporal stability (Fig 1).

Intra-assay reliability was assessed by calculating the median coefficient of variation (CV), or relative standard deviation, for duplicate sample concentrations within each of the 3 plates. Inter-assay reliability was assessed by calculating CV values for duplicate samples across three experimental blocks and tested statistically using intra-class correlation coefficients (ICCs) [45,46]. ICC estimates and 95% Confidence Intervals (CIs) were calculated using SPSS Statistics 24.0 based on ICC(3,3), a mean-rating, absolute agreement, 2-way mixed-effects model (recommended in [47]). Mean normalization was first applied to each plate to correct for day-to-day technical variation, before calculation of the CV. Analytes with both intra- and inter-assay CVs below 15% were considered to have acceptable technical reliability. Data were natural-logarithm transformed prior to ICC analysis. ICCs were interpreted as follows: ICCs > 0.75 indicated strong reliability, ICCs between 0.5–0.75 reflected moderate to good reliability, and ICCs < 0.5 indicated poor reliability [48].

Samples from subjects in the placebo group were used for the intra-individual biotemporal variation assessment of each analyte that passed the technical precision criteria. Paired CSFs collected at baseline and after the first treatment block (8 weeks apart) were used to calculate CV values representing the biotemporal stability of analytes. The mean concentrations for each sample across the three experimental blocks was used for analysis. ICCs were not calculated for biotemporal variation as the sample size was not sufficient to satisfy test conditions. Similarly, given that analyte distribution could not be assumed to be normal, a Wilcoxon Signed-Ranks Test was used to assess whether there were significant differences between CSF collection timepoints. Finally, an analyte with a calculated biotemporal CV below 15% was considered to have low baseline variability.

Results
Assay sensitivity for analytes in CSF
A total of 35 CSF samples collected from twenty study participants were included in this analysis. Five samples were unavailable due to an unsuccessful lumbar puncture or subject refusal. Assay sensitivity was assessed for twenty single-plex and multi-plex assays used in this study (Table 2). Percentages of sample measurements with concentrations falling above the LLOD were calculated using concentrations from all sample replicates across the three experimental blocks. In total, 105 measurements per biomarker were taken into consideration to determine whether the target protein could be reliably detected and measured in CSF (S1 Table and S1 Fig).

For the four core AD biomarkers (tTau, \(\text{A} \beta_{1-38}\), \(\text{A} \beta_{1-40}\), and \(\text{A} \beta_{1-42}\)) and the three \(\text{A} \beta\) and tau-independent “neurodegeneration” markers neurofilament light-chain (NFL), \(\alpha\)-Synuclein, and fatty acid binding protein 3 (FABP3), all 105 sample concentrations were measurable well above the LLOD, as expected.
Of the 30 inflammatory/immune markers, sixteen were measurable in all samples (eotaxin-3, IP-10, MCP-1, MDC, MIP-1α, MIP-1β, TARC, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-6, IL-8, SAA, CRP, and YKL-40). IL-5, IL-10, and eotaxin were measurable in > 90% of samples (96/105, 101/105, and 101/105, respectively). IFN-γ was measurable in 89.52% (94/105) of CSF samples, and TNF-α was measurable in 80.95% (85/105). The remaining nine inflammatory markers (MCP-4, IL-17A, IL-1α, TNF-β, IL-1β, IL-2, IL-4, IL-13, and Tie-2) did not meet assay sensitivity criteria, with < 80% of all measured samples falling above the qualifying LLOD threshold.

The thirteen neurovascular biomarkers were considered measurable in CSF, with ten of those analytes measurable in all 105 assayed samples including the matrix metalloproteinases MMP-1, MMP-2, MMP-3, and MMP-10, vascular endothelial growth factor (VEGF) and the VEGFR receptor (Flt-1), VEGF-D, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and phosphatidylinositol-glycan biosynthesis class F protein (PIGF). The neurovascular markers MMP-9 and VEGF-C were measurable in > 90% of samples (101/105 and 104/105, respectively), and fibroblast growth factor-basic (FGF-basic) was measurable in 89.52% (94/105) of assayed samples.

Four of the ten metabolic markers were measurable in all CSF samples: 24S-hydroxycholesterol (24-OHC), adiponectin, soluble insulin receptor (sIR), and 8-hydroxydeoxy guanosine (8-OHdG). Leptin was measurable in 84.29% (59/70) of included samples. Active glucagon like protein-1 (GLP-1), glucagon, and carboxymethyl lysine (CML) were not detectable in any CSF samples using the applied methods. Insulin was not considered measurable in CSF (only 54.29% of sample concentrations fell above the LLOD), but because of interest in this metabolic hormone in AD [7,8] we pursued it with three alternative commercial assays, though none yielded better results. The VGF nerve growth factor inducible (VGF) immunoassay was not reproducible in our hands and was discontinued (S1 Table).

**Technical precision: Intra-assay reliability**

Analyses of intra-assay reliability were performed only if biomarker candidates were measurable in > 80% of cases in the initial sensitivity screening. Analytes with marginal concentrations in CSF might be expected to exhibit poor precision and reliability due to their proximity to the LLOD [49]. Therefore, insulin, active GLP-1, glucagon, CML, MCP-4, IL-17A, IL-1α, TNF-β, IL-1β, IL-2, IL-4, IL-13, and Tie-2 were excluded from subsequent analyses.

Forty-two of the remaining 46 analytes met acceptable intra-assay reliability criteria (S1 Table). The four core AD biomarkers (tTau, Aβ1–38, Aβ1–40, and Aβ1–42) and three neurodegenerative markers (α-Synuclein, FABP3, and NfL) had excellent intra-assay precision (CVs < 5%). All five metabolic and oxidative stress markers (24-OHC, adiponectin, leptin, sIR, and 8-OHdG) and eleven of the thirteen neurovascular markers (MMP-1, MMP-2, MMP-3, MMP-10, Flt-1, ICAM-1, PIGF, VCAM-1, VEGF, VEGFC, and VEGFD) also had intra-assay CVs below 5%. Two neurovascular markers, MMP-9 and FGF (basic), had intra-assay CVs below 10%, which met acceptable intra-assay criteria.

The inflammatory analytes were the only class to include some intra-assay CVs that did not meet predetermined precision criteria. Fifteen of the 21 inflammatory analytes (IP-10, MCP-1, MIP-1α, IL-6, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-6, IL-8, IL-10, TNF-α, SAA, CRP, and YKL-40) exhibited excellent or acceptable intra-assay precision with CV values below 15%. Two inflammatory candidates (IFN-γ and MDC) nearly made the acceptable threshold (15.47% and 15.75%, respectively), and were kept under consideration due to their proximity to the acceptability criteria. Three candidates (eotaxin-3, MIP-1α, and TARC) had intra-assay CVs between 16–20%, and one candidate, eotaxin, had poor intra-assay precision (27.35%). These four analytes were excluded from further analyses.
Technical replicability: Inter-assay reliability

Inter-assay reliability was assessed using ICC(3,3) taking into account the mean concentrations of each sample \((n = 35)\) measured across three experimental blocks. The overall inter-assay CV for each biomarker candidate was evaluated by calculating the CV between all technical replicates across the three experimental blocks after applying a mean-normalization adjustment to sample concentrations on repeated assays. Both analytical methods were used to stringently identify candidates with the best overall inter-assay replicability (i.e. exhibiting both ICC reliability > 0.5 and an inter-assay CV < 15%). Failure to meet performance criteria under either analysis served as an indication of poor inter-assay replicability.

All ICC(3,3) coefficients for the 42 biomarker candidates still in consideration were significant \((p < 0.05)\). Thirty-five of these analytes demonstrated acceptable inter-assay reliability (S2 Table).

As anticipated, the four core AD biomarkers (tTau, A\(_{\beta 1–38}\), A\(_{\beta 1–40}\), and A\(_{\beta 1–42}\)) exhibited both strong inter-assay reliability (ICC > 0.75) and inter-assay CVs below 15%. Likewise, all five metabolic markers (adiponectin, leptin, sIR, 8-OHdG, and 24-OHC) exhibited strong inter-assay reliability (ICC > 0.75) and inter-assay CVs below 15%. Two of the three neurodegenerative markers (FABP3 and NfL) met acceptable inter-assay criteria under both analyses (ICC > 0.5 and CV < 15%). Although \(\alpha\)-Synuclein had an ICC of 0.8 (indicating strong reliability when transformed to a normally-distributed dataset), it did not meet acceptable inter-assay CV criteria (CV: 16.76%) and was discounted.

Of the thirteen neurovascular markers, two analytes (MMP-9 and FGF (basic)) were excluded based on poor inter-assay CVs (19.25% and 23.94%, respectively) despite having ICCs > 0.75. The remaining eleven neurovascular markers (MMP-1, MMP-2, MMP-3, MMP-10, Flt-1, ICAM-1, PIGF, VCAM-1, VEGF, VEGF-C, and VEGF-D) were classified as having strong inter-assay reliability under the combined analysis (ICC > 0.75, CV < 15%).

Ten of the seventeen inflammatory markers (MCP-1, MIP-1\(\beta\), IL-7, IL-12/IL-23p40, IL-6, IL-8, IL-10, SAA, CRP, and YKL-40) had acceptable CV values (< 15%) in addition to strong inter-assay reliability (ICC > 0.75). An additional three inflammatory analytes (MDC, IL-15, and IL-16) exhibited moderate inter-assay reliability (ICC: 0.5–0.75, CV < 15%). The remaining four inflammatory candidates (IFN-\(\gamma\), IP-10, IL-5, and TNF-\(\alpha\)) were excluded based on either poor ICC reliability (ICC < 0.5) or failure to meet acceptable inter-assay CV criteria of < 15%.

Biotemporal intra-individual variation

The biotemporal variation of each analyte was determined through analysis of mean concentrations for paired CSFs collected from subjects in the placebo group \((n = 9)\) at baseline and again eight weeks later after the first treatment block (Fig 2 and Table 3). This analysis was performed for the 35 analytes that passed the assay sensitivity, intra-assay and inter-assay precision screenings and remained under consideration as promising candidates. As testing distributions for normality suggested that normality could not be assumed, a Wilcoxon Signed-Ranks Test was used to evaluate whether there were any statistically significant observed differences between paired CSFs. None of the 35 analytes examined showed statistically significant differences between repeat-collected samples \((p > 0.05)\), however three exceeded our CV < 15% criterion for acceptable biotemporal stability, including SAA, CRP, and IL-10. The remaining 32 met acceptable biotemporal stability criteria (CV < 15%), including the four core AD markers (tTau, A\(_{\beta 1–38}\), A\(_{\beta 1–40}\), and A\(_{\beta 1–42}\)), the two remaining neurodegenerative markers (NfL and FABP3), and the five metabolic markers (24-OHC, adiponectin, leptin, soluble IR, and 8-OHdG). All eleven neurovascular markers that met inter-assay reliability criteria...
(MMP-1, MMP-2, MMP-10, Flt-1, ICAM-1, PI GF, VCAM-1, VEGF, VEGF-C, and VEGF-D) also exhibited acceptable biotemporal stability (CV < 15%), as did ten of the remaining thirteen inflammation markers (MCP-1, MDC, MIP-1β, IL-7, IL-12/23p40, IL-15, IL-16, IL-6, IL-8, and YKL-40).

Raw data for all analytes included in the study are provided in S3 Table.

**Discussion**

We performed comprehensive fit-for-purpose testing of commercially available immunoassays in CSF and identified a broad selection of reliably measured, biotemporally stable markers that represent multiple pathophysiological domains of interest in AD. In examining both technical reliability and biotemporal stability in CSF (S2 Fig), we established baseline variability in analyte measures, a prerequisite for the design and interpretation of biomarker measures in studies of differential diagnosis, disease staging, and tracking of longitudinal change with disease progression or intervention response.

Biotemporal stability is often overlooked as a measure of assay reliability, but is important as metabolic, vascular, inflammatory, and other markers may fluctuate or otherwise vary over
Table 3. Intra-individual biostability of analyte measurements between repeat-collected CSFs.

| Analyte                  | Mean baseline concentration (SD) | Mean follow-up concentration (SD) | Median biotemporal CV, % (IQR) | Exact p-value (2-tailed) |
|--------------------------|---------------------------------|----------------------------------|---------------------------------|--------------------------|
| **Core AD biomarkers**   |                                 |                                  |                                 |                          |
| Aβ1–40 (pg/mL)           | 2274.36 (780.95)                | 2221.92 (727.66)                 | 4.31 (2.39–7.22)                | 0.496                    |
| Aβ1–42 (pg/mL)           | 5625.73 (1724.57)               | 5503.12 (1664.84)                | 4.87 (2.86–7.30)                | 0.570                    |
| Total Tau (pg/mL)        | 343.35 (102.86)                 | 345.14 (108.33)                  | 9.26 (6.02–13.75)               | 0.820                    |
| **Aβ and tau-independent neurodegeneration biomarkers** |                                 |                                  |                                 |                          |
| α-Synuclein (pg/mL)      | 1010.23 (365.59)                | 1244.30 (856.46)                 | 24.10 (13.13–48.79)             | 0.910                    |
| FABP3 (ng/mL)            | 6.24 (1.91)                     | 6.27 (2.09)                      | 3.94 (2.63–5.76)                | 0.652                    |
| NfL (pg/mL)              | 2275.26 (728.83)                | 2287.14 (755.59)                 | 6.37 (4.51–7.69)                | 0.652                    |
| **Metabolic and oxidative stress biomarkers** |                                 |                                  |                                 |                          |
| 8-OHdG (ng/mL)*          | 0.34 (0.12)                     | 0.40 (0.19)                      | 11.76 (8.74–13.84)              | 0.844                    |
| 24-OHC (ng/mL)           | 5.08 (1.74)                     | 4.93 (1.67)                      | 8.20 (5.80–10.01)               | 0.734                    |
| Adiponectin (ng/mL)      | 15.50 (10.73)                   | 16.77 (13.08)                    | 10.81 (10.45–25.24)             | 0.734                    |
| Leptin (pg/mL)           | 721.38 (380.45)                 | 732.71 (382.84)                  | 2.03 (1.58–5.22)                | 0.820                    |
| **Inflammatory biomarkers** |                                 |                                  |                                 |                          |
| CRP (pg/mL)              | 2725.01 (1812.81)               | 3820.46 (3511.84)                | 22.86 (15.50–42.45)             | 0.426                    |
| IFN-γ (pg/mL)            | 0.35 (0.13)                     | 0.35 (0.10)                      | 21.44 (14.74–30.04)             | 1.000                    |
| IL-5 (pg/mL)             | 3.07 (0.94)                     | 3.16 (0.91)                      | 7.81 (4.76–9.70)                | 0.359                    |
| IL-6 (pg/mL)             | 1.33 (0.44)                     | 1.29 (0.47)                      | 7.67 (5.51–8.82)                | 0.496                    |
| IL-7 (pg/mL)             | 1.98 (0.72)                     | 1.93 (0.56)                      | 4.81 (3.28–9.33)                | 0.652                    |
| IL-8 (pg/mL)             | 49.56 (5.70)                    | 48.05 (9.84)                     | 6.13 (2.90–10.32)               | 0.426                    |
| IL-10 (pg/mL)            | 4.79 (1.07)                     | 4.70 (0.96)                      | 7.79 (4.44–9.84)                | 0.383                    |
| IL-12/IL-23p40 (pg/mL)   | 7.35 (2.37)                     | 8.03 (3.14)                      | 3.67 (1.02–8.54)                | 1.000                    |
| IL-15 (pg/mL)            | 8.16 (1.39)                     | 7.80 (0.94)                      | 8.69 (5.59–12.23)               | 0.426                    |
| IL-16 (pg/mL)            | 13.66 (3.16)                    | 15.71 (7.27)                     | 10.45 (2.90–13.90)              | 0.570                    |
| IP-10 (pg/mL)            | 328.05 (189.96)                 | 417.52 (300.40)                  | 26.58 (19.69–33.60)             | 0.426                    |
| MCP-1 (pg/mL)            | 552.04 (184.84)                 | 527.03 (179.64)                  | 4.72 (2.44–9.43)                | 0.129                    |
| MDC (pg/mL)              | 18.83 (3.75)                    | 21.63 (11.05)                    | 14.69 (10.44–21.62)             | 1.000                    |
| MIP-1β (pg/mL)           | 11.55 (2.51)                    | 12.38 (4.28)                     | 6.15 (5.55–8.06)                | 0.359                    |
| TNF-α (pg/mL)            | 0.09 (0.03)                     | 0.14 (0.13)                      | 14.15 (2.74–27.08)              | 0.426                    |
| SAA (pg/mL)              | 1580.41 (840.94)                | 1738.68 (1282.62)                | 22.15 (15.25–45.54)             | 0.652                    |
| YKL-40 (pg/mL)           | 356214.83 (104425.28)           | 360437.47 (100814.79)            | 1.68 (0.60–6.30)                | 0.910                    |
| **Neurovascular biomarkers** |                                 |                                  |                                 |                          |
| FGF (basic) (pg/mL)      | 0.56 (0.62)                     | 1.27 (2.84)                      | 72.89 (48.10–103.55)            | 1.000                    |
| Flt-1 (pg/mL)            | 76.82 (27.02)                   | 78.47 (27.88)                    | 6.21 (3.45–6.59)                | 0.820                    |
| ICAM-1 (pg/mL)           | 2681.35 (791.79)                | 2678.38 (815.11)                 | 3.43 (2.76–5.73)                | 0.910                    |
| MMP-1 (pg/mL)            | 25.42 (0.37)                    | 29.07 (11.35)                    | 4.06 (3.19–8.44)                | 0.570                    |
| MMP-2 (pg/mL)            | 2470.42 (4339.36)               | 24440.73 (4896.25)               | 1.80 (1.19–3.40)                | 0.910                    |
| MMP-3 (pg/mL)            | 549.29 (258.35)                 | 574.36 (328.08)                  | 4.61 (3.55–6.81)                | 0.652                    |
| MMP-9 (pg/mL)            | 186.74 (89.13)                  | 249.82 (215.74)                  | 22.46 (14.81–54.49)             | 0.734                    |
| MMP-10 (pg/mL)           | 100.85 (59.74)                  | 108.39 (67.40)                   | 2.37 (0.73–7.95)                | 0.129                    |
| PlGF (pg/mL)             | 108.86 (39.56)                  | 102.45 (29.22)                   | 3.63 (2.00–5.33)                | 0.301                    |
| VCAM-1 (pg/mL)           | 8709.32 (2019.20)               | 8657.81 (2088.87)                | 1.55 (0.65–4.15)                | 1.000                    |
| VEGF (pg/mL)             | 4.48 (2.18)                     | 3.76 (1.07)                      | 9.70 (3.47–16.16)               | 0.098                    |
| VEGF-C (pg/mL)           | 71.45 (30.62)                   | 61.10 (25.06)                    | 13.04 (2.82–17.93)              | 0.129                    |

(Continued)
time. Analyte levels might be affected by circadian or seasonal rhythms, diet, environmental stressors, and intercurrent health issues. Such factors may compromise the comparative utility of these biomarkers, underscoring the importance of determining intra-individual variation prior to their inclusion as biomarkers in longitudinal studies or clinical trials. Determining baseline fluctuation of analytes also has statistical implications for the interpretation of both cross-sectional and longitudinal data, and can inform study design and sample size necessary to reveal significant differences in the primary outcomes of clinical trials.

From our initial screening of 60 unique protein/molecular targets, we identified 32 promising markers that were measurable in CSF, passed our technical reliability performance criteria of better than 15% CV, and presented low intra-individual variation between repeat collected samples. The panel of high performing candidate analytes we identified represent important pathophysiological domains in AD—including neurodegeneration, inflammation/immune modulation, neurovascular injury, metabolism and oxidative stress—allowing for multi-pathway profiling of disease state. Their performance criteria would qualify these assays in research, though better performance would be necessary for clinical use. In addition, the multiplexed nature of these assays requires that more testing be performed if they are to be used in long-term studies, when different "lots" of assay kits might be used over time. Multiplexed assays are more subject to lot to lot variability, cross reactivity issues, and matrix effects than single-plex assays, and as a result should be assessed for spike recovery and parallelism on a lot-to-lot basis [50].

Each of the core AD CSF biomarkers tested (tTau, Aβ1–38, Aβ1–40, and Aβ1–42) performed well in every measure, meeting the fit-for-purpose standards of sensitivity and stability for the MSD assays. These results were in agreement with published data evaluating the analytic performance of these proteins on this platform [51]. Of the non-core analytes, the non-Aβ and non-tau neurodegeneration markers NfL and FABP3 were also remarkably stable over a two-month interval, with comparable analytic performance to the classical AD markers. NfL is considered to be a marker of damage to large myelinated axons, and FABP3 is an abundant cytoplasmic protein that is thought to participate in the uptake, intracellular metabolism, and/or transport of long-chain fatty acids, playing a role in composition of lipid membranes [52–54]. NfL and FABP3 have both been reported to correlate with t′tau [18,55] and/or Aβ [56]. However, neither is thought to be disease specific, but rather general markers of neurodegeneration [54,57–59]. They may be useful as complementary biomarkers for staging AD or perhaps quantifying the amount or degree of active neurodegeneration at the time of the sample.

Abnormalities in inflammatory cytokines, chemokines, and immune modulators have been reported in AD, but replications have been less consistent. Among the more robust has been the secreted glycoprotein YKL-40 [18,60–63], while data are less consistent on others such as monocyte chemokine MCP-1 [64,65] and proinflammatory cytokine IL-6 [66]. The value of these inflammatory analytes as biomarkers in the diagnosis, prognosis, or progression of AD/
ADRD remains to be seen, but we can confirm the reliability and stability of their measurement for this purpose. In addition, we found that seven other inflammatory/immune molecules, not heretofore reported in CSF, also demonstrated good performance characteristics, including the interleukins IL-7, IL-12/23p40, IL-15, IL-16, and IL-8, MDC and MIP-1β.

The role of neurovascular injury has been of increasing interest in AD, but relevant biomarkers are not well established. Some of the more commonly reported include adhesion molecules ICAM-1 and VCAM-1 [67,68]. We identified eleven potential biomarkers (Table 2) of relevance to neurovascular injury that were reliably measurable in CSF and exhibited good biotemporal stability. Having established a method of reliably replicating the measurement of these markers will assist future studies investigating their roles in the pathogenesis of AD/ADRDs.

Many markers of metabolism and oxidative stress are reported to be present at very low concentrations in CSF compared to plasma or serum [69–71]. We were especially interested in measuring insulin levels in CSF, as insulin resistance is of great current interest in the field [7,72] and insulin levels have previously been reported to be altered in the CSF of AD patients [73]. Using MSD and three additional commercial assays for insulin we found very low concentrations in CSF, at or below the lower limits of detection. Further work, perhaps with new, ultrasensitive single molecule array assays will be needed to reliably measure this important metabolic hormone in CSF for AD studies.

Of the initial ten metabolism/oxidative stress biomarkers we surveyed, only five were reliably measurable in CSF, including sIR, adipokines adiponectin and leptin, the brain specific cholesterol metabolite 24-OHC, and oxidative stress related DNA modification 8-OHdG. Abnormalities in essential metabolic pathways, including trophic and metabolic signaling and regulation and cholesterol trafficking and turnover, have been reported in AD and associated with disease severity [74–78]. The relatively few reports prompt interest, and we hope the validation data we provide enable further study in this important area.

In conclusion, we have identified a pathophysiologically diverse set of CSF biomarkers that demonstrate consistent, reliable, and biotemporally stable quantification, establishing their potential for use in exploratory studies of AD. Subsequent work will assess the value of these high performing assays for inclusion in a practical biomarker panel for multi-dimensional molecular profiling in dementia as a tool for diagnosis and staging as well as assessing disease mechanisms, novel therapeutic target engagement of drugs or other biological interventions, and response in clinical trials. We conjecture that analyte profiles will differ among patients to varying degrees, thus allowing a personalized profile that may suggest a personalized treatment or prevention strategy.

Supporting information

S1 Fig. Assay sensitivity performance for CSF collected from subjects with MCI or mild dementia due to AD. (PDF)

S2 Fig. Promising candidates that exhibited good technical replicability and biotemporal stability. (PDF)

S1 Table. Descriptive statistics of study samples. (XLSX)

S2 Table. Inter-assay reliability characteristics of biomarkers reliably measurable in CSF. (XLSX)
S3 Table. Raw data for all analytes included in the study.
(XLSX)

Author Contributions

Conceptualization: Steven E. Arnold.

Data curation: Bianca A. Trombetta, Steven E. Arnold.

Formal analysis: Bianca A. Trombetta, Joseph J. Locascio, Steven E. Arnold.

Funding acquisition: Leslie M. Shaw, John Q. Trojanowski, Steven E. Arnold.

Investigation: Bianca A. Trombetta.

Methodology: Bianca A. Trombetta, Aaron M. Koenig, Joseph J. Locascio, Steven E. Arnold.

Project administration: Aaron M. Koenig, Steven E. Arnold.

Resources: Leslie M. Shaw, John Q. Trojanowski, David A. Wolk, Steven E. Arnold.

Supervision: Aaron M. Koenig, Steven E. Arnold.

Validation: Bianca A. Trombetta.

Visualization: Bianca A. Trombetta.

Writing – original draft: Bianca A. Trombetta, Becky C. Carlyle, Aaron M. Koenig, Steven E. Arnold.

Writing – review & editing: Bianca A. Trombetta, Becky C. Carlyle, Aaron M. Koenig, Leslie M. Shaw, John Q. Trojanowski, David A. Wolk, Joseph J. Locascio, Steven E. Arnold.

References

1. Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu Rev Biochem. 2017; 86: 27–68. https://doi.org/10.1146/annurev-biochem-061516-045115 PMID: 28498720

2. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015; 16: 358–72. https://doi.org/10.1038/nrn3880 PMID: 25991443

3. Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017; 23: 1018–1027. https://doi.org/10.1038/nm.4397 PMID: 28886007

4. Santos CY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer’s Dement (Amsterdam, Netherlands). 2017; 7: 69–87. https://doi.org/10.1016/j.dadm.2017.01.005 PMID: 28275702

5. Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowski P, Pera J, et al. Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol. 2016; 53: 4094–4125. https://doi.org/10.1007/s12035-015-9337-5 PMID: 26198567

6. Kim GH, Kim JE, Rhie SJ, Yoon S. The Role of Oxidative Stress in Neurodegenerative Diseases. Exp Neurol. 2015; 24: 325–40. https://doi.org/10.5607/en.2015.24.3.325 PMID: 26713080

7. Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012; 122: 1316–38. https://doi.org/10.1172/JCI59903 PMID: 22476197

8. Ribe EM, Lovestone S. Insulin signalling in Alzheimer’s disease and diabetes: from epidemiology to molecular links. J Intern Med. 2016; 280: 430–442. https://doi.org/10.1111/j.1253 PMID: 27739227

9. Boehm J. A “danse macabre”: tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity. Eur J Neurosci. 2013; 37: 1925–30. https://doi.org/10.1111/ejn.12251 PMID: 23773061
Canter RG, Penney J, Tsai L-H. The road to restoring neural circuits for the treatment of Alzheimer’s disease.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease. Neuron. 2013; 80: 1347–58.

Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013; 80: 1347–58.

Briggs CA, Chakroverty S, Stutzmann GE. Emerging pathways driving early synaptic pathology in Alzheimer’s disease. Neurochem Int. 2017; 108: 355–360.

Zetterberg H. Applying fluid biomarkers to Alzheimer’s disease. Am J Physiol Cell Physiol. 2017; 313: C3–C10. https://doi.org/10.1152/ajpcell.00007.2017 PMID: 28024166

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. NIH Public Access; 2009; 65: 403–13. https://doi.org/10.1002/ana.21610 PMID: 19296504

Skillbäck T, Zetterberg H, Blennow K, Mattsson N. Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimers Res Ther. 2013; 5: 47. https://doi.org/10.1186/alzrt212 PMID: 24479774

Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, et al. Diagnostic accuracy of CSF biomarkers for Alzheimer’s disease. Acta Neurol Scand. 2015; 132: 221–227. https://doi.org/10.1111/ane.12329 PMID: 25582743

Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med. 2016; 8: 1184–1196. https://doi.org/10.15252/emmm.201606540 PMID: 27534871

Lewczuk P, Riederer P, O’Bryant SE, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2017; 1: 85. https://doi.org/10.1080/15622975.2017.1375556 PMID: 29076399

Cummings J, Zhong K. Biomarker-driven therapeutic management of Alzheimer’s disease: establishing the foundations. Clin Pharmacol Ther. 2014; 95: 67–77. https://doi.org/10.1038/clpt.2013.205 PMID: 24105258

Beach TG. A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley? Neuror Ther. 2017; 6: 5–13. https://doi.org/10.1007/s40102-017-0072-x PMID: 28739861

Ritter A, Cummings J. Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics. Front Neurol. 2015; 6: 186. https://doi.org/10.3389/fneur.2015.00186 PMID: 26379620

Mattsson N, Carillo MC, Dean RA, Devous MD, Nikolaeva T, Pesini P, et al. Revolutionizing Alzheimer’s disease and clinical trials through biomarkers. Alzheimer’s Dement (Amsterdam, Netherlands). Elsevier; 2015; 1: 412–9. https://doi.org/10.1016/j.jadm.2015.09.001 PMID: 27239522

Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A. Pre-analytical and analytical factors influencing Alzheimer’s disease cerebrospinal fluid biomarker variability. Clin Chim Acta. 2015; 449: 9–15. https://doi.org/10.1016/j.cca.2015.05.024 PMID: 26141614

Rozga M, Bittner T, Höglund K, Blennow K. Accuracy of cerebrospinal fluid Aβ1–42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunoassay. Clin Chem Lab Med. 2017; 55: 1545–1554. https://doi.org/10.1515/cclm-2016-1061 PMID: 28160541

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014; 13: 614–29. https://doi.org/10.1016/S1474-4422(14)70090-0 PMID: 24849862

Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer’s disease: current limitations and recent developments. Curr Opin Psychiatry. 2015; 28: 402–9. https://doi.org/10.1097/YCO.0000000000000179 PMID: 26147615

Wu AHB. Analytical validation of novel cardiac biomarkers used in clinical trials. Am Heart J. 2015; 169: 674–83. https://doi.org/10.1016/j.ahj.2015.01.016 PMID: 25965715

Wu D, Dinh TL, Bausk BP, Wall DR. Long-Term Measurements of Human Inflammatory Cytokines Reveal Complex Baseline Variations between Individuals. Am J Pathol. 2017; 187: 2620–2626. https://doi.org/10.1016/j.ajpath.2017.08.007 PMID: 28919109
32. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, et al. Longitudinal stability of CSF biomarkers in Alzheimer’s disease. Neurosci Lett. 2007; 419: 18–22. https://doi.org/10.1016/j.neulet.2007.03.064 PMID: 17482358
33. Buchhave P, Blennow K, Zetterberg H, Stromrud E, Londos E, Andreassen N, et al. Longitudinal Study of CSF Biomarkers in Patients with Alzheimer’s Disease. Heutink P, editor. PLoS One. Public Library of Science; 2009; 4: e6294. https://doi.org/10.1371/journal.pone.0006294 PMID: 19609443
34. Le Bastard N, Aerts L, Sleegers K, Martin J-J, Van Broeckhoven C, De Deyn PP, et al. Longitudinal Stability of Cerebrospinal Fluid Biomarker Levels: Fulfilled Requirement for Pharmacodynamic Markers in Alzheimer’s Disease. J Alzheimer’s Dis. IOS Press; 2013; 33: 807–822. https://doi.org/10.3233/JAD-2012-110029 PMID: 23034521
35. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis. 2012; 30: 767–78. https://doi.org/10.3233/JAD-2012-120019 PMID: 22475796
36. Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O. Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer’s disease: A prospective 9-year study. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2015; 1: 403–411. https://doi.org/10.1016/j.dadm.2015.09.002 PMID: 27239521
37. Hofmann JN, Yu K, Bagri RK, Lan Q, Rothman N, Purdue MP. Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. Cytokine. 2011; 56: 145–8. https://doi.org/10.1016/j.cytjo.2011.06.012 PMID: 21764327
38. Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From A Randomized Placebo-controlled Cross-over Study. Alzheimer Dis Assoc Discrord. 2017; 31: 107–113. https://doi.org/10.1097/WAD.000000000000202 PMID: 28590888
39. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43: 2412–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/8323972
40. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189–98. Available: http://www.ncbi.nlm.nih.gov/pubmed/1202204 PMID: 1202204
41. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 17: 37–49. Available: http://www.ncbi.nlm.nih.gov/pubmed/7183759 PMID: 7183759
42. Hachinski V, Oveisgharan S, Romney AK, Shankle WR. Optimizing the Hachinski Ischemic Scale. Arch Neurol. 2012; 69: 169–75. https://doi.org/10.1001/archneurol.2011.1698 PMID: 21987392
43. R Foundation for Statistical Computing. R: A language and environment for statistical computing. R: A Language and Environment for Statistical Computing 3.3.1. 2016.
44. RStudio Team -. RStudio: Integrated Development for R. [Online] RStudio, Inc, Boston, MA URL http://www.rstudio.com. 2016; https://doi.org/10.1007/978-81-322-2340-5
45. Shroot PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86: 420–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/18839484 PMID: 18839484
46. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996; 1: 30–46. https://doi.org/10.1037/1082-989X.1.1.30
47. Portney LG, Watkins MP. Statistical measures of reliability. Foundations of clinical research: applica-
48. tions to practice. 2000.
49. Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From A Randomized Placebo-controlled Cross-over Study. Alzheimer Dis Assoc Discrord. 2017; 31: 107–113. https://doi.org/10.1097/WAD.000000000000202 PMID: 28590888
50. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43: 2412–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/8323972
51. Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From A Randomized Placebo-controlled Cross-over Study. Alzheimer Dis Assoc Discrord. 2017; 31: 107–113. https://doi.org/10.1097/WAD.000000000000202 PMID: 28590888
53. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis. 2010; 22: 1281–8. https://doi.org/10.3233/JAD-2010-101293 PMID: 20930282

54. Olsson B, Hertz J, Ohlsson M, Närgå K, Höglund K, Basun H, et al. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013; 34: 673–9. https://doi.org/10.3233/JAD-121384 PMID: 23254629

55. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007; 4: 366–75. https://doi.org/10.1159/000105157 PMID: 17622779

56. Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, et al. Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration. Mol Neurodegener. 2013; 8: 39. https://doi.org/10.1186/1750-1326-8-39 PMID: 24088526

57. Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. Reindl M, editor. PLoS One. 2013; 8: e75091. https://doi.org/10.1371/journal.pone.0075091 PMID: 24073237

58. Hansson O, Janelidze S, Hall S, Magdalinoú N, Lees AJ, Andreasson U, et al. Blood-based NIL. Neurology. 2017; 88: 930–937. https://doi.org/10.1212/01.WNL.0000000000003680 PMID: 28179466

59. Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, et al. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia. Alzheimers Res Ther. 2017; 9: 52. https://doi.org/10.1186/s13195-017-0276-4 PMID: 28750675

60. Llorens F, Thuné K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017; 12: 83. https://doi.org/10.1186/s13024-017-0226-4 PMID: 29126445

61. Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017; 14: 285–299. https://doi.org/10.1080/14789450.2017.1304217 PMID: 28281838

62. Muszyński P, Grobiewska M, Kulczyńska-Przybik A, Kulakowska A, Mończko B. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease. Curr Neuropharmacol. 2017; 15: 906–917. https://doi.org/10.2174/1570159X15666170208124324 PMID: 28183245

63. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies. Bartres-Faz D, editor. PLoS One. 2015; 10: e0135458. https://doi.org/10.1371/journal.pone.0135458 PMID: 26270969

64. Popp J, Okonomides A, Tautvydaitė D, Dayon L, Bacher M, Miglaivacca E, et al. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav Immun. 2017; 62: 203–211. https://doi.org/10.1016/j.bbi.2017.01.020 PMID: 28161476

65. Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, et al. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer’s disease dementia phenotypes. Alzheimer’s Dement (Amsterdam, Netherlands). 2016; 3: 91–7. https://doi.org/10.1016/j.dadm.2016.05.004 PMID: 27453930

66. Wennström M, Hall S, Närgå K, Londos E, Minthon L, Hansson O. Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Alzheimers Res Ther. 2015; 7: 63. https://doi.org/10.1186/s13195-015-0145-y PMID: 26434635

67. Huang C-W, Tsai M-H, Chen N-C, Chen W-H, Lu Y-T, Lui C-C, et al. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer’s dementia. Thromb Haemost. 2015; 114: 1230–40. https://doi.org/10.1160/TH14-11-0938 PMID: 26289958

68. Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, et al. Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2013; 35: 363–71. https://doi.org/10.3233/JAD-122359 PMID: 23403534

69. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998; 50: 164–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/9443474 PMID: 9443474

70. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996; 2: 589–93. Available: http://www.ncbi.nlm.nih.gov/pubmed/8616722 PMID: 8616722

71. Cha E, Lee KM, Park KD, Park KS, Lee K-W, Kim S-M, et al. Hydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag-CIS/MS/MS and
72. Yarchoan M, Arnold SE. Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease. Diabetes. 2014; 63: 2253–2261. https://doi.org/10.2337/db14-0287 PMID: 24931035

73. Neth BJ, Craft S. Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages. Front Aging Neurosci. 2017; 9: 345. https://doi.org/10.3389/fnagi.2017.00345 PMID: 29163128

74. Trushina E, Dutta T, Persson X-MT, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. PLoS One. Public Library of Science; 2013; 8: e63644. https://doi.org/10.1371/journal.pone.0063644 PMID: 23700429

75. Hughes TM, Rosano C, Evans RW, Kuller LH. Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis. 2013; 33: 891–911. https://doi.org/10.3233/JAD-2012-121585 PMID: 23076077

76. Testa G, Staurenghi E, Zerbinati C, Gargiulo S, Iuliano L, Giaccone G, et al. Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation. Redox Biol. 2016; 10: 24–33. https://doi.org/10.1016/j.redox.2016.09.001 PMID: 27687218

77. Zarrouk A, Debbabi M, Bezine M, Karym EM, Badreddine A, Rouaud O, et al. Lipid Biomarkers in Alzheimer’s Disease. Curr Alzheimer Res. 2017; 14: 1–1. https://doi.org/10.2174/156720501466617050501426 PMID: 28474568

78. Gmitterová K, Heinemann U, Gawinecka J, Varges D, Ciesielczyk B, Valkovic P, et al. 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases. Neurodegener Dis. 2009; 6: 263–9. https://doi.org/10.1159/000237221 PMID: 19955696